EPO and chronic kidney disease: In the patients with CKD, treated by dialysis, Chen et al. [18] observed serum hepcidin basal concentrations to be 180.7 ± 136.8 ng/mL and changing at week 23 of the study by −30.2 ± 113.3 ng/mL in the roxadustat group, while in the alpha erythropoietin group, serum hepcidin basal concentrations were 148 ± 105.2 ng/mL and changed by −2.3 ± 130.7 ng/mL [18].